Additional file 1: of Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors
Imke H. Bartelink(University of California, San Francisco), Laura van ât Veer, Byron Hann(University of California, San Francisco), Diane Heditsian(University of California, San Francisco), Lisa J. Wilmes(University of California, San Francisco), Douglas Yee(University of Minnesota Medical Center), Nela Pawłowska(University of California, San Francisco), Hilde Rosing(The Netherlands Cancer Institute), Ella F. Jones(University of California, San Francisco), Lamorna Swigart-Brown(UCSF Helen Diller Family Comprehensive Cancer Center), Brendan Prideaux(Hackensack Meridian Health), Sergey Magnitsky(University of California, San Francisco), Laura Esserman(UCSF Helen Diller Family Comprehensive Cancer Center), Rahul Aggarwal(UCSF Helen Diller Family Comprehensive Cancer Center), Pamela N. Münster(University of California, San Francisco), Gregor Krings(Cleveland Clinic), Niels de Vries(The Netherlands Cancer Institute), Mallika Sachdev Dhawan, Weiming Ruan(University of California, San Francisco), Ron J. Keizer, VĂŠronique Dartois, Jean-Philippe CoppĂŠ, Scott Thomas, Pan Bo, Pei Lee, Radojka M. Savić(University of California, San Francisco), Alan Wu, Denise M. Wolf
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k